Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: A randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kanungo, Suman ^b   Sen, Bandana ^a   Ramamurthy, Thandavarayan ^b   Sur, Dipika ^b   Manna, Byomkesh ^b   Pazhani, Gururaja P ^b   Chowdhury, Goutam ^b   Jhunjhunwala, Puja ^b   Nandy, Ranjan K ^b   Koley, Hemanta ^b   Bhattacharya, Mihir Kumar ^b   Gupta, Sanjay ^c   Goel, Gaurav ^c   Dey, Bindu ^d   M, Thungapathra ^e   Nair, G Balakrish ^f   Ghosh, Amit ^b   Mahalanabis, Dilip ^a  

^a SOCIETY FOR APPLIED STUDIES   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c Catalyst Clinical Services Pvt Ltd   (India)

^d DEPARTMENT OF BIOTECHNOLOGY   (India)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f Translational Health Science and Technology Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASCORBIC ACID; BICARBONATE; CHOLERA TOXIN; CHOLERA VACCINE; ORAL RECOMBINANT CHOLERA VACCINE VA1.4; PLACEBO; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; RECOMBINANT VACCINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACKACHE; CHOLERA; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; INDIA; LOSS OF APPETITE; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; SHELF LIFE; SINGLE DRUG DOSE; VOMITING; ADOLESCENT; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 84903708929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099381     Document Type: Article

References (25)

1. Weekly epidemiological Record (2010) WHO, No. 13, 85: 117-128.
2. Weekly epidemiological record (2013) WHO, No. 31, 88: 321-336.
3. Thungapathra M, Sharma C, Gupta N, Ghosh RK, Mukhopadhyay A, et al. (1999) Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholera O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunol Lett 68: 219-27. (Pubitemid 29301880)
4. Mahalanabis D, Ramamurthy T, Nair GB, Ghosh A, Shaikh S, et al. (2009) Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA 1.3 for safety and immune response. Vaccine 27: 4850-6.
5. Benenson As, Saad A, Mosley WH (1968) Serological Studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ 38: 277-85.
6. Nandy RK, Albert MJ, Ghose AC (1996) Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholera O139 Bengal and evaluation of their importance in protection Vaccine 14: 1137-42. (Pubitemid 26348832)
7. Varela P, Rivas M, Binsztein N, Cremona ML, Herrmann P, et al. (1993) Identification of toxigenic Vibrio cholerae from the Argentine outbreak by PCR for ctx A1 and ctx A2-B. FEBS Lett 315: 74-76. (Pubitemid 23005734)
8. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, et al. (2008) A randomized placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3: e2323.
9. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, et al. (2005) Peru-15 Study Group. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis. 15; 192(4): 573-9. Epub 2005 Jul 15.
10. Chowdhury F, Khan AI, Harris JB, LaRocque RC, Chowdhury MI, et al. (2008) A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J. 27(11): 986-92. doi:10.1097/INF.0b013e3181783adf.
11. Mosley WH, Ahmad S, Benenson As, Ahmed A (1968) The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ; 38: 777-85.
12. Mosley WH, Benenson AS, Barui R (1968) A serological survey for cholera antibodies in rural east Pakistan 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ 38: 327-34.
13. Mosley WH, Ahmed A (1969) Active and passive immunization in the adult rabbit ileal loop model as an assay for production of antitoxin immunity by cholera vaccines. J Bacteriol 100: 547-9.
14. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, et al. (1985) Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236-42. (Pubitemid 15162711)
15. Clemens JD, van Loon F, Sack DA, Chakraborty J, Rao MR, et al. (1991) Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 163: 1235-42.
16. Levine MM, Kaper JB (1993) Live oral vaccines against cholera: an update. Vaccine 11: 207-12. (Pubitemid 23031509)
17. Levine MM, Pierce NF (1992) Immunity and vaccine development. In: Greenough III WB, Barua D, editors. Cholera. New York: Plenum Publishing Corporation 285-327.
18. Saha D, LaRocque RC, Khan AI, Harris JB, Bagum YA, et al. (2004) Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholera infection in urban Bangladesh. J Infec Dis 189: 2318-22. (Pubitemid 38757206)
19. Fujita K, Finkelstein RA (1972) Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice. J Infect Dis 125: 647-55.
20. Holmgren J, Svennerholm AM, Ouchterlony O, Anderson A, Walletstrom G, et al. (1975) Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun 12: 1331-40.
21. Pierce NF, Sack RB, Sircar BK (1977) Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral toxoid administration to dogs. J Infect Dis 135: 888-96. (Pubitemid 8112538)
22. Pierce NF, Reynolds HY (1974) Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol 113: 1017-23.
23. Peterson JW (1979) Protection against experimental cholera by oral or parenteral immunization, Infect Immun 26: 594-98.
24. th Joint Conference on Cholera, U.S.-Japan Cooperative Medical Science Program. Sapporo. Fuji, Tokyo 302-10.
25. Raychoudhuri A, Chatterjee S, Pazhani GP, Nandy RK, Bhattacharya MK, et al. (2007) Molecular characterization of recent Vibrio Cholerae O1, El TOR, Inaba strains isolated from hospitalized patients in Kolkata, India. J Infect 55: 431-8. (Pubitemid 47611513)